Dichloroacetic acid and rapamycin synergistically inhibit tumor progression / 浙江大学学报(英文版)(B辑:生物医学和生物技术)
Journal of Zhejiang University. Science. B
; (12): 397-405, 2023.
Article
em En
| WPRIM
| ID: wpr-982380
Biblioteca responsável:
WPRO
ABSTRACT
Mammalian target of rapamycin (mTOR) controls cellular anabolism, and mTOR signaling is hyperactive in most cancer cells. As a result, inhibition of mTOR signaling benefits cancer patients. Rapamycin is a US Food and Drug Administration (FDA)-approved drug, a specific mTOR complex 1 (mTORC1) inhibitor, for the treatment of several different types of cancer. However, rapamycin is reported to inhibit cancer growth rather than induce apoptosis. Pyruvate dehydrogenase complex (PDHc) is the gatekeeper for mitochondrial pyruvate oxidation. PDHc inactivation has been observed in a number of cancer cells, and this alteration protects cancer cells from senescence and nicotinamide adenine dinucleotide (NAD+) exhaustion. In this paper, we describe our finding that rapamycin treatment promotes pyruvate dehydrogenase E1 subunit alpha 1 (PDHA1) phosphorylation and leads to PDHc inactivation dependent on mTOR signaling inhibition in cells. This inactivation reduces the sensitivity of cancer cells' response to rapamycin. As a result, rebooting PDHc activity with dichloroacetic acid (DCA), a pyruvate dehydrogenase kinase (PDK) inhibitor, promotes cancer cells' susceptibility to rapamycin treatment in vitro and in vivo.
Palavras-chave
Texto completo:
1
Índice:
WPRIM
Assunto principal:
Complexo Piruvato Desidrogenase
/
Sirolimo
/
Ácido Dicloroacético
/
Serina-Treonina Quinases TOR
/
Alvo Mecanístico do Complexo 1 de Rapamicina
/
Neoplasias
Limite:
Humans
Idioma:
En
Revista:
Journal of Zhejiang University. Science. B
Ano de publicação:
2023
Tipo de documento:
Article